Currently, however, research is necessary to construct a PROTAC whose POI would be IDH, as well as to determine the effectiveness of the aforementioned approach in the treatment of AML or glioma with an IDH mutation in vivo in preclinical studies. Here, IDH1 is linked to acute myeloid leukemia.